Login / Register 
United States ($) USD
Austria (€) EUR
Belgium (€) EUR
Finland (€) EUR
France (€) EUR
Germany (€) EUR
Ireland (€) EUR
Japan (¥) JPY
Luxembourg (€) EUR
Netherlands (€) EUR
Switzerland (CHF) CHF
United Kingdom (£) GBP
- Regulatory Status
- RUO
- Other Names
- Bone Morphogenetic Protein 3, Osteogenin, Bone Morphogenetic Protein 3 (Osteogenic), Bone Morphogenetic Protein 3A, BMP-3A, BMP-3, BMP3A
- Ave. Rating
- Submit a Review
- Product Citations
- publications
-
Recombinant human BMP-3 inhibits the activity of BMP-2 in MC3T3-E1 mouse preosteoblast cells. The ED50 for this effect is 8 – 40 µg/mL. -
Stability Testing for Recombinant Human BMP-3. Human BMP-3 was aliquoted in 35% Acetonitrile, 0.1% TFA at 0.2 mg/mL. One aliquot was frozen and thawed four times (4x Freeze/Thaw) and compared to the control that was kept at 4°C (Control). The samples were tested for their ability to inhibit the activity of BMP-2 in in MC3T3-E1 mouse preosteoblast cells. The ED50 for this effect is 8 – 40 µg/mL.
| Cat # | Size | Price | Quantity Check Availability | Save | ||
|---|---|---|---|---|---|---|
| 792206 | 100 µg | £230 | ||||
Bone morphogenetic protein 3 (BMP-3) belongs to the TGF-β superfamily. Like other members of the BMP family, BMP-3 is synthesized as an inactive propeptide precursor which dimerizes and then it is further processed into its mature form. BMP-3 was initially purified from bone as osteogenin; nevertheless, it does not have osteogenic activity. BMP-3 is an antagonist of osteogenic BMPs such as BMP-2, 4, and 7; BMP-3 inhibits differentiation of osteoprogenitor cells into osteoblasts induced by BMP-2. BMP-3 antagonizes the BMP type II receptor ActRIIB and negatively regulates bone density. BMP-3 is expressed in late stages of inflammatory arthritis by osteoblasts in erosion sites. BMP-3 has been associated with colorectal cancer and gastric carcinoma. Overexpression of BMP-3 during skeletal development modifies endochondral bone formation resulting in spontaneous rib fractures. BMP-3 -/- mice have augmented bone volume and density.
Product DetailsProduct Details
- Source
- Human BMP-3, amino acid (Gln363-Arg472) (Accession No. P12645), was expressed in E.coli. The amino terminus contains Met.
- Molecular Mass
- The 113 amino acid recombinant protein has a predicted molecular mass of approximately 12.7 kD. The DTT-reduced and non-reduced protein migrates at approximately 12 kD and 35-40 kD by SDS-PAGE, respectively. The predicted N-terminal amino acid is Met.
- Purity
- >95%, as determined by Coomassie stained SDS-PAGE.
- Formulation
- 0.22 μm filtered protein solution is in 35% Acetonitrile, 0.1% TFA
- Endotoxin Level
- Less than 0.1 EU per µg cytokine as determined by the LAL method
- Concentration
- 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
- Storage & Handling
- Unopened vial can be stored between 2°C and 8°C for up to 2 weeks at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2ᵒC and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
- Activity
- Recombinant human BMP-3 inhibits the activity of BMP-2 in MC3T3-E1 mouse preosteoblast cells. The ED50 for this effect is 8 – 40 µg/mL.
- Application
-
Bioassay
- Application Notes
-
BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are validated in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.
Antigen Details
- Structure
- Homodimer
- Distribution
-
Osteoblasts, osteoclasts, chondroblasts, adult bone
- Function
- Inhibits osteoblast differentiation, negatively regulates bone density. TNF induces BMP-3 expression in rat dental follicle cells and osteoblasts.
- Interaction
- Osteoblasts, osteoclasts, chondroblasts, osteoprogenitor cells, mesenchimal stem cell
- Ligand/Receptor
- BMP-3 binds to the BMP type II receptor ActRIIB
- Bioactivity
- Recombinant human BMP-3 inhibits the activity of BMP-2 in MC3T3-E1 mouse preosteoblast cells.
- Antigen References
-
- Daluiski A, et al. 2001. Nat Genet. 27:84.
- Loh K, et al. 2010. Genes Chromosomes Cancer. 47:449.
- Chen XR, et al. 2010. World J Gastroenterol. 16:1409.
- Gamer LW, et al. 2009. Dev Dyn. 238:2374.
- Yao S, et al. 2010. Connect Tissue Res. 51:59.
- Kokabu S, et al. 2012. Mol Endocrinol. 26:87.
- Matzelle MM, et al. 2016. Scand J Rheumatol. 45:379.
- Gene ID
- 651 View all products for this Gene ID
- Specificity (DOES NOT SHOW ON TDS):
- BMP-3
- Specificity Alt (DOES NOT SHOW ON TDS):
- BMP-3
- App Abbreviation (DOES NOT SHOW ON TDS):
- BA
- UniProt
- View information about BMP-3 on UniProt.org
Related FAQs
- Why choose BioLegend recombinant proteins?
-
• Each lot of product is quality-tested for bioactivity as indicated on the data sheet.
• Greater than 95% Purity or higher, tested on every lot of product.
• 100% Satisfaction Guarantee for quality performance, stability, and consistency.
• Ready-to-use liquid format saves time and reduces challenges associated with reconstitution.
• Bulk and customization available. Contact us.
• Learn more about our Recombinant Proteins. - How does the activity of your recombinant proteins compare to competitors?
-
We quality control each and every lot of recombinant protein. Not only do we check its bioactivity, but we also compare it against other commercially available recombinant proteins. We make sure each recombinant protein’s activity is at least as good as or better than the competition’s. In order to provide you with the best possible product, we ensure that our testing process is rigorous and thorough. If you’re curious and eager to make the switch to BioLegend recombinants, contact your sales representative today!
- What is the specific activity or ED50 of my recombinant protein?
-
The specific activity range of the protein is indicated on the product datasheets. Because the exact activity values on a per unit basis can largely fluctuate depending on a number of factors, including the nature of the assay, cell density, age of cells/passage number, culture media used, and end user technique, the specific activity is best defined as a range and we guarantee the specific activity of all our lots will be within the range indicated on the datasheet. Please note this only applies to recombinants labeled for use in bioassays. ELISA standard recombinant proteins are not recommended for bioassay usage as they are not tested for these applications.
- Have your recombinants been tested for stability?
-
Our testing shows that the recombinant proteins are able to withstand room temperature for a week without losing activity. In addition the recombinant proteins were also found to withstand four cycles of freeze and thaw without losing activity.
- Does specific activity of a recombinant protein vary between lots?
-
Specific activity will vary for each lot and for the type of experiment that is done to validate it, but all passed lots will have activity within the established ED50 range for the product and we guarantee that our products will have lot-to-lot consistency. Please conduct an experiment-specific validation to find the optimal ED50 for your system.
- How do you convert activity as an ED50 in ng/ml to a specific activity in Units/mg?
-
Use formula Specific activity (Units/mg) = 10^6/ ED50 (ng/mL)
Follow Us